||Career Development Fellowship (CDF)
Safety and Efficacy of High Dose Rifampicin in TB-HIV co-infected patients on Efavirenz-based Antiretroviral therapy
1. To determine the effect of a high dose of rifampicin (35 mg/kg orally) on the pharmacokinetics of first-line antiretroviral drugs (efavirenz and dolutegravir) in TB-HIV co-infected patients on TB treatment.
1. To investigate the safety/tolerability of a high dose of rifampicin in TB-HIV co-infected patients on TB treatment and first-line antiretroviral therapies.
2. To determine if TB-HIV co-infected patients on a high dose of rifampicin are more likely to have negative sputum cultures by the end of the intensive phase of TB treatment than patients on standard-dose rifampicin.
3. To explore the relationships between exposure to rifampicin, efavirenz and dolutegravir and the tolerability and efficacy of these drugs.
|Makerere University - IDI
Randomized four-arm open label clinical trial (Phase IIb)
High dose rifampicin will be administered for the first 8 weeks (intensive phase) of TB treatment. All other anti-TB drugs will be administered at the standard dose using fixed-dose combinations (FDC). All participants will receive standard dose rifampicin during the continuation phase (weeks 9 -24)
|Correlating rifampcin and isoniazid concentrations with treatment outcomes in TB/HIV co-infected patients
||Makerere University/University of Zurich
Results & Outcomes
Sub-therapeutic rifampicin and isoniazid concentrations in up to 84% of population which was associated with delayed sputum conversion
No association between drug concentrations and sputum smear conversion is not surprising
Efavirenz associated with 20% increase in isoniazid clearance
Infectious Diseases Institute
Current Job Title
Areas Of Specialisation
Human Immuno-deficiency Virus (HIV)
Message send successfully!
Send a Message